Rosa Gonzalez-quevedo

Dr. Rosa Gonzalez-quevedo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
ICIndiana Castro
Indiana Castro
MTMarie Van Tricht
Marie Van Tricht
NBNicole Bonaccorso
Nicole Bonaccorso
MSMartina Sciortino
Martina Sciortino
JBJuan Garcia Burgos
Juan Garcia Burgos
RGRosa Gonzalez-quevedo
Rosa Gonzalez-quevedo
The COVID-19 pandemic posed challenges to communicating accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reassure the public by communicating early on about the development and approval of COVID-19 vaccines. The EMA surveyed patients/consumers, healthcare professional organizations, and individual stakeholders, both at the EU level and in an Italian regional context. The objectives of the study were to see if the EMA’s core information materials were informative and well-understood and which communication channels were preferred by the public. The main findings showed that individual patients/consumers generally prefer to obtain information about COVID-19 vaccines from the internet or mass media, while organizations and individual healthcare professionals prefer to obtain information from national and international health authorities. Both at EU and local levels, participants had a good understanding of the key messages from regulators and found the materials useful and relevant. However, some improvements were recommended to the visual, text, and dissemination formats, including publishing more information on safety and using a more public-friendly language. Also, it was recommended to maintain the EMA’s approach of using media, stakeholder engagement, and web-based formats to communicate about COVID-19 vaccines. In conclusion, user-testing of proactive communication materials aimed to prebunk misinformation during a public health crisis helps to ensure that users understand the development and safety of novel vaccine technologies. This information can then be used as a basis for further evidence-based communication activities by regulators and public health bodies in an emergency context.

21 July 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
MTMaribel Gonzalez Tome
Maribel Gonzalez Tome
RGRosa Gonzalez-quevedo
Rosa Gonzalez-quevedo
MSMaria dos Santos
Maria dos Santos
HDHans Juergen Dornbusch
Hans Juergen Dornbusch
SSSabine Straus
Sabine Straus
ECEmer Cooke
Emer Cooke
Background: Neisseria meningitidis B is one of the main causative pathogens of meningitis and other forms of severe meningococcal disease. In the past decade, meningococcal B vaccines have been developed to address this infection and its sequelae. Objective: This article aims to present an example of how the EU regulatory framework allowed the early authorisation of two life-saving vaccines initially based on immunogenicity surrogates of clinical evidence. This was subsequently followed by post-marketing surveillance providing real-world evidence to support their safety profile and impact on the paediatric population in the EU. Methods: We review the evidence supporting the initial regulatory approval of the vaccines, the confirmatory data demonstrating vaccine effectiveness post-authorisation, and the real-world impact of these vaccines on the paediatric population. Results: Two vaccines were approved in the EU for active immunisation to prevent IMD caused by MenB (4CMenB in 2013 and MenB-fHBP in 2017). Both marketing authorisations were based on immunogenicity data (efficacy studies were not feasible due to the rarity of the disease) and safety data generated from pre-authorisation studies. Additional pharmacovigilance activities to further investigate the safety profile and effectiveness studies were requested to be conducted after approval. Both the effectiveness and safety profile of the vaccines were confirmed by these data. Conclusions: This paper illustrates that the EU medicines regulatory framework and safety monitoring system are robust. By supplementing the initial evidence with post-authorisation studies, further effectiveness and safety data enabled regulators to confirm the positive benefit–risk of the vaccines without delaying their access to the people who need them.

14 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ICIndiana Castro
Indiana Castro
MTMarie Van Tricht
Marie Van Tricht
NBNicole Bonaccorso
Nicole Bonaccorso
MSMartina Sciortino
Martina Sciortino
JBJuan Garcia Burgos
Juan Garcia Burgos
RGRosa Gonzalez-quevedo
Rosa Gonzalez-quevedo
The COVID-19 pandemic made it harder to communicate accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reas-sure the public by communicating about the development and approval of COVID-19 vaccines. They surveyed patients/consumers, healthcare professional organizations, and individual stake-holders to see if their core information materials were informative and well understood. They also asked about the public's preferred communication channels. The surveys showed that indi-vidual patients/consumers generally prefer to get information about COVID-19 vaccines from the internet or mass media. Organizations and individual healthcare professionals prefer to get in-formation from national and international health authorities' sources. This supports EMA's ap-proach of using media, stakeholder engagement, and web-based formats to communicate about COVID-19 vaccines. Both at the EU and local levels, participants had a good understanding of the key messages from regulators and found the materials useful and relevant. However, some im-provements were recommended to the visuals, texts, and dissemination formats. These recom-mendations were generally consistent in both contexts. User-testing of proactive communication materials aimed at prebunking misinformation during a public health crisis helps to ensure that users understand the development and safety safeguards of novel vaccine technologies. This in-formation can then be used as a basis for evidence-based communication activities by regulators and public health bodies in an emergency context.

13 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
ICIndiana Castro
Indiana Castro
MTMarie Van Tricht
Marie Van Tricht
NBNicole Bonaccorso
Nicole Bonaccorso
MSMartina Sciortino
Martina Sciortino
JBJuan Garcia Burgos
Juan Garcia Burgos
RGRosa Gonzalez-quevedo
Rosa Gonzalez-quevedo
The author would like to make the following correction to this publication